Impact of cholinesterase inhibitors or memantine on survival in adults with Down syndrome and dementia: clinical cohort study
| Autor: | Jane McCarthy, Simon Bonell, J. Bernal, Amanda Sinai, David Thomas, Sharma, Kamalika Mukherji, Khadija Rantell, Richard Hillier, Andre Strydom, Dina Gazizova, Ingrid Bohnen, Judith McBrien, Ken Courtenay, Natalia Perez-Achiaga, Zuzana Walker, Rory Sheehan, Angela Hassiotis, Karen Dodd, N Eady, Asim Naeem |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Down syndrome
medicine.medical_specialty biology business.industry MEDLINE Memantine Disease medicine.disease Comorbidity 03 medical and health sciences Psychiatry and Mental health 0302 clinical medicine Internal medicine medicine biology.protein Dementia 030212 general & internal medicine business 030217 neurology & neurosurgery Cholinesterase medicine.drug Cohort study |
| Zdroj: | Eady, N, Sheehan, R, Rantell, K, Sinai, A, Bernal, J, Bohnen, I, Bonell, S, Courtenay, K, Dodd, K, Gazizova, D, Hassiotis, A, Hillier, R, Mcbrien, J, Mukherji, K, Naeem, A, Perez-Achiaga, N, Sharma, V, Thomas, D, Walker, Z, McCarthy, J & Strydom, A 2018, ' Impact of cholinesterase inhibitors or memantine on survival in adults with Down syndrome and dementia : clinical cohort study ', British Journal of Psychiatry, vol. 212, no. 3, pp. 155-160 . https://doi.org/10.1192/bjp.2017.21 |
| ISSN: | 1472-1465 0007-1250 |
| Popis: | BackgroundThere is little evidence to guide pharmacological treatment in adults with Down syndrome and Alzheimer's disease.AimsTo investigate the effect of cholinesterase inhibitors or memantine on survival and function in adults with Down syndrome and Alzheimer's disease.MethodThis was a naturalistic longitudinal follow-up of a clinical cohort of 310 people with Down syndrome diagnosed with Alzheimer's disease collected from specialist community services in England.ResultsMedian survival time (5.59 years, 95% CI 4.67–6.67) for those on medication (n = 145, mainly cholinesterase inhibitors) was significantly greater than for those not prescribed medication (n = 165) (3.45 years, 95% CI 2.91–4.13, log-rank test PConclusionsCholinesterase inhibitors appear to offer benefit for people with Down syndrome and Alzheimer's disease that is comparable with sporadic Alzheimer's disease; a trial to test the effect of earlier treatment (prodromal Alzheimer's disease) in Down syndrome may be indicated.Declaration of interestA.S. has undertaken consulting for Ono Pharmaceuticals, outside the submitted work. Z.W. has received a consultancy fee and grant from GE Healthcare, outside the submitted work. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|